公开(公告)号：US20160319003A1

公开(公告)日：2016-11-03

申请号：US15143162

申请日：2016-04-29

申请人： President and Fellows of Harvard College ,  UCB Biopharma SPRL

发明人： Gökhan S. Hotamisligil ,  Mehmet F. Burak ,  Feyza Engin ,  Scott B. Widenmaier ,  Elisabeth Helen Roberts ,  Adrian Richard Moore ,  Carl Brendan Doyle ,  Ralph Adams ,  Karine Jeannine Madeleine Hervé ,  Shauna Mhairi Wales ,  Kerry Louise Tyson

IPC分类号： C07K16/18

CPC分类号： C07K16/18 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/6018 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92

摘要： This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

摘要翻译： 本发明涉及改进的抗αP2抗体和抗原结合剂及其组合物，其靶向脂质伴侣aP2 / FABP4（称为“aP2”），用于治疗疾病如糖尿病，肥胖症，心血管疾病 ，脂肪肝疾病和/或癌症等。 一方面，公开了aP2介导的疾病的改进治疗，其中血清aP2是靶向的，并且使用低结合亲和性aP2单克隆抗体中和或调节aP2的生物学活性，提供较低的空腹血糖水平，改善的全身葡萄糖代谢，增加 全身胰岛素敏感性，脂肪量减少，肝脂肪变性减少，心血管疾病降低和/或发生心血管疾病风险降低。

公开(公告)号：US20200377578A1

公开(公告)日：2020-12-03

申请号：US16919576

申请日：2020-07-02

申请人： UCB Biopharma SPRL

发明人： David Paul Humphreys ,  Daniel John Lightwood ,  Kerry Louise Tyson ,  David Edward Ormonde Knight ,  Karine Jeannine Madeleine Hervé ,  Joanne Elizabeth Compson ,  Matthew Jon Timothy Page ,  Andrew Charles Payne ,  Nicola Louise Fisher ,  Brendon MacKenzie ,  Matthew Cox

IPC分类号： C07K16/12 ,  A61K39/40 ,  A61K45/06 ,  G01N33/569 ,  G01N33/573 ,  G01N33/68

摘要： This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.

公开(公告)号：US10160798B2

公开(公告)日：2018-12-25

申请号：US15143162

申请日：2016-04-29

申请人： President and Fellows of Harvard College ,  UCB Biopharma SPRL

发明人： Gökhan S. Hotamisligil ,  Mehmet F. Burak ,  Feyza Engin ,  Scott B. Widenmaier ,  Elisabeth Helen Roberts ,  Adrian Richard Moore ,  Carl Brendan Doyle ,  Ralph Adams ,  Karine Jeannine Madeleine Hervé ,  Shauna Mhairi Wales ,  Kerry Louise Tyson

IPC分类号： C07K16/18 ,  A61K39/00

摘要： This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

公开(公告)号：US20190161536A1

公开(公告)日：2019-05-30

申请号：US16197066

申请日：2018-11-20

申请人： President and Fellows of Harvard College ,  UCB Biopharma SPRL

发明人： Gökhan S. Hotamisligil ,  Mehmet F. Burak ,  Feyza Engin ,  Scott B. Widenmaier ,  Elisabeth Helen Roberts ,  Adrian Richard Moore ,  Carl Brendan Doyle ,  Ralph Adams ,  Karine Jeannine Madeleine Hervé ,  Shauna Mhairi Wales ,  Kerry Louise Tyson

IPC分类号： C07K16/18 ,  A61K39/00

摘要： This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

公开(公告)号：US09908939B2

公开(公告)日：2018-03-06

申请号：US14914676

申请日：2014-08-26

申请人： UCB BIOPHARMA SPRL

发明人： Graham Craggs ,  Karine Jeannine Madeleine Hervé ,  Diane Marshall

IPC分类号： C07K16/28 ,  C07K16/00 ,  C12P21/08 ,  A61K39/00

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention relates to an anti-CSF-1R antibody and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The present invention also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment.